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Letter to the Editor 
Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients  
treated with hydroxychloroquine/chloroquine: New case reports coming out      
Afra TP et al comment our recent report entitled: “acute hemolysis 
by hydroxychloroquine (HCQ) was observed in G6PD-deficient patient 
with severe COVID-19 related lung injury” [1,2]. Afra et al. underlight 
”confounding factors and inconsistencies” in our conclusion, linking 
acute drop in Hb in COVID-19 patient with suspected G6PD and HCQ 
treatment. We respectfully disagree with comments from Afra et al. Our 
case report was the first one of a series, linking G6PD deficiency with 
HCQ/CQ treatment for COVID19 infection such as Kuiper ME et al. or 
Beauverd Y et al. or Maillart et al. [3–5]. In our case, we observed an 
acute drop of Hb values associated with the appearance of hemoglo-
binuria and abnormalities in red cell morphology at the blood smear 
within 48 h after patient hospital admission and the introduction of 
HCQ treatment. Our patient was transfused and HCQ was withdrawn 
with stabilization of Hb values. Thus, this was not a spontaneous re-
covery of Hb values as suspected by Afra et al. (see Fig. 1 in De Fran-
ceschi L et al 2020) [2]. In addition, hemoglobinuria is a hallmark of 
intravascular hemolysis, which characterizes drug induced acute he-
molysis in G6PD patients [6]. Otherwise, drug induced hemolytic an-
emia in patients with healthy red cells is general an extravascular he-
molysis without hemoglobinuria. 
Italy is an endemic area for G6PD deficiency [6]. Our patient was 
suspected for G6PD deficiency based on previous hemolytic events re-
corded in patient history. To fully answer the question raised by Afra 
et al., we have evaluated G6PD activity in our patients at 8 weeks after 
hospital discharge. As expected we found G6PD deficiency with normal 
complete blood count analysis and normal reticulocyte count (43.500 
retics/uL). 
Collectively our results and the post-recovery determination of 
G6PD support the link between acute hemolysis and HCQ/CQ treatment 
in COVID-19 patients. 
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